October 7, 2015
In a prospective study, the presence of circulating tumor cells was found to be associated with a decreased overall survival in patients with cholangiocarcinoma, suggesting it may be a useful biomarker for tumor prediction.
Lewis R. Roberts, MB, ChB, PhD, division of gastroenterology and hepatology, Mayo Clinic, Rochester, Minn., and colleagues reviewed medical records of 88 patients with cholangiocarcinoma (CCA) enrolled at Mayo Clinic, Rochester, between June 2010 and September 2014. To determine if any circulating tumor cells (CTC) were present, blood samples were collected after CCA diagnosis. The CellSearch System (Veridex LLC) was used for detection of CTCs in peripheral blood, according to the research.